Study on the mechanism by which apolipoprotein(apo) E2 promotes diabetic nephropathy

载脂蛋白(apo)E2促进糖尿病肾病的机制研究

基本信息

  • 批准号:
    14571112
  • 负责人:
  • 金额:
    $ 1.66万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2002
  • 资助国家:
    日本
  • 起止时间:
    2002 至 2003
  • 项目状态:
    已结题

项目摘要

Background and Aim : In 1994 we first demonstrated that the apolipoprotein(apo) E ε2 allele is associated with the progression of diabetic nephropathy. Apo E2 is well known to contribute to high plasma levels of remnant lipoproteins. The aim of the present study is to further investigate the association between apo E genetic polymorphism, remnant lipoproteins and diabetic nephropathy.Subjects and Methods : Type 2 diabetic patients who had a diabetes duration over 10 years were divided into the 3 apo E groups ; apo E2(n=22),E3/3(n=102) and E4(n=34). Plasma levels of lipids and remnant lipoproteins were measured. Histologic studies were performed using renal biopsy specimens in apo E2 patient. The effects of apo E2-IDL(remnant lipoproteins) on cultured human mesangial cells were studied.Results : The frequency of overt nephropathy was significantly higher in apo E2 diabetic patients(59.1%) than in apo E3/3(34.3%) or apo E4 patients(8.8%), and there was also a significant difference in the frequency of overt nephropathy between apo E3/3 and E4 groups. Plasma levels of triglyceride and remnant-like lipoprotein particles(RLP)-chol and were significantly higher in apo E2 patients, and significantly lower in apo E4 patients than in apo E3/3 patients. Logistical regression analysis showed that odds ratios of high plasma remnant(RLP-C≧5.2mg/dl) for the presence of overt nephropathy were 3.614(p=0.0208). Histological renal change of apo E2 patient was almost identical to diabetic nephropathy. Immunohistochemically, apo E and apo B were stained in glomerulus of apo E2 patient. Apo E2-IDL stimulated significantly PKC activity, TGF-b synthesis, and type IV collagen and fibronectin synthesis in mesangial cells sa compared with apo E3/3-IDL.Conclusion : Remnant lipoproteins may have an important role in the progression of diabetic nephropathy.
背景:1994年,我们首先证明了载脂蛋白(APO)Eε2等位基因与糖尿病性apo apo e2有助于高血浆脂肪素的目的。在遗传多态性,残留的脂蛋白和糖尿病性肾病之间。受试者和mitchods:2个在10年内糖尿病持续时间的糖尿病患者分为3个apo e2(n = 22),e3 /3 = e3 /3(n = 22) 102)和E4(n = 34)。 Apo E2糖尿病在Apo E3/3(34.3%)或APO E4患者(8.8%)中han,并且Apo E3/3和E4组之间的明显肾病也存在显着差异。 Apo E2患者的明显高,Apo E4患者显着高于In in in in。与APO A3 /3-IDL相比, - IIDL刺激了TLY PKC活性,TGF-B合成和IV型胶原蛋白和纤连蛋白合成。

项目成果

期刊论文数量(36)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Saito M, Eto M, Nitta H, et al.: "Effect of apolipoprotein E4 allele on plasma LDL-cnolesterol response to diet therapy in type 2 diabetic patients"Diabetes Care. (In press).
Saito M、Eto M、Nitta H 等人:“载脂蛋白 E4 等位基因对 2 型糖尿病患者饮食疗法对血浆 LDL-胆固醇反应的影响”糖尿病护理。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Hamano M, Saito M, Eto M et al.: "Serum amyloid A (SAA), C-reactive protein (CRP) and remnant-like lipoprotein particles (RLP)-cholesterol in type 2 diabetic patients with coronary heart disease"Ann Clin Biochem. (In press).
Hamano M、Saito M、Eto M 等人:“患有冠心病的 2 型糖尿病患者的血清淀粉样蛋白 A (SAA)、C 反应蛋白 (CRP) 和残余样脂蛋白颗粒 (RLP)-胆固醇”Ann Clin
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Eto M, Saito M, Nakata H: "Type III hyperlipoproteinemia with apolipoprotein E2/2 genotype in Japan"Clinical Genetics. 61. 416-422 (2002)
Eto M、Saito M、Nakata H:“日本载脂蛋白 E2/2 基因型的 III 型高脂蛋白血症”临床遗传学。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Hamano M, Saito M, Eto M, Nishimatsu S, Matsuda M, Matsuki M, Suda H, Yamamoto S, Kaku K.: "Serum amylod A(SAA), C-reactive protein(CRP) and remnant-like lipoprotein particles(RLP)-cholesterol in type 2 diabetic patients with coronary heart disease."Ann C
Hamano M、Saito M、Eto M、Nishimatsu S、Matsuda M、Matsuki M、Suda H、Yamamoto S、Kaku K.:“血清淀粉样蛋白 A(SAA)、C 反应蛋白(CRP)和残留样脂蛋白颗粒(
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Eto M, Saito M, Okada M, Kume Y, Kawasaki F, Matsuda M, Yoneda M, Matsuki M, Takigami S, Kaku K.: "Apolipoprotein E genetic polymorphism, remanat lipoproteins and nephropathy in type 2 diabetic patients."Am J Kidney Dis. 40. 243-251 (2002)
Eto M、Saito M、Okada M、Kume Y、Kawasaki F、Matsuda M、Yoneda M、Matsuki M、Takigami S、Kaku K.:“载脂蛋白 E 遗传多态性、残余脂蛋白和 2 型糖尿病患者的肾病。”Am J
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ETO Masaaki其他文献

ETO Masaaki的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ETO Masaaki', 18)}}的其他基金

Risk factors for diabetic nephropathy (apolipoprotein E2 allele and remnant lipoproteins) and drug intervention
糖尿病肾病的危险因素(载脂蛋白E2等位基因和残余脂蛋白)及药物干预
  • 批准号:
    19590155
  • 财政年份:
    2007
  • 资助金额:
    $ 1.66万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Diabetic nephropathy and apolipoprotein E2 allele
糖尿病肾病与载脂蛋白E2等位基因
  • 批准号:
    12671128
  • 财政年份:
    2000
  • 资助金额:
    $ 1.66万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Study on the significance of apo E in aherosclerosis
apo E在动脉粥样硬化中的意义研究
  • 批准号:
    05670407
  • 财政年份:
    1993
  • 资助金额:
    $ 1.66万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了